Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
ACN Newswire能提供全方位的服務。對於希望向媒體、業界和金融市場披露和傳播資訊的公司和組織,我們能為您安排即時的新聞發佈。ACN Newswire的新聞稿包括英文、簡體中文、繁體中文、韓文和日文等多種語言版本。
Tuesday, 12 September 2023, 21:22 HKT/SGT
Share:

來源 Ad Scientiam
Ad Scientiam Launches International Study to Assess Disability Progression in Multiple Sclerosis With MSCopilot

PARIS, FRANCE, 2023年9月12日 - (亞太商訊)  - Ad Scientiam, a global leader in digital biomarkers, has announced a partnership with Sanofi to launch MS-DETECT, an international, multicenter, longitudinal study. MS-DETECT aims to evaluate the ability of MSCopilot(R), a medical software device, to detect early signs of disability worsening in people with multiple sclerosis (PwMS). The study will draw upon Ad Scientiam's expertise in MS and is financially supported by Sanofi.

Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that affects 2.8 million people worldwide. The disease is characterized by early inflammatory demyelination and subsequent neurodegeneration. Current clinical evaluation of PwMS relies mainly on the Expanded Disability Status Scale (EDSS), which has several limitations. To improve on these assessments, Ad Scientiam has developed MSCopilot(R), a software medical device that addresses four dimensions: ambulation/mobility, upper extremity function, cognition, and low-contrast visual acuity.

MS-DETECT's main objective is to determine MSCopilot(R)'s ability to identify subtle and early disability worsening. This will be performed by evaluating MSCopilot(R) individual and/or composite scores as compared to the Multiple Sclerosis Functional Composite (MSFC) and the EDSS.

"MS-DETECT is a pioneering large-scale longitudinal study that explores digital biomarkers for the early detection of disease progression. This study will provide important data to both clinicians and people living with MS," according to Dr. Saad Zinai, Chief Medical Officer at Ad Scientiam.

"Disability worsening in MS has been recently redefined and we now know that this progression can occur independently of relapses. With MS-DETECT, we have an opportunity to develop a digital solution to help detect and monitor the effects of smoldering disease, and evolve treatment goals for MS patients," explains Su-Peing Ng, Global Head of Medical Affairs - Specialty Care at Sanofi.

The study also aims to assess the MSCopilot(R) performance, safety, usability and satisfaction with the solution.

"Disease progression can be hard to detect in routine practice. I believe these novel digital biomarkers are key to help clinicians make appropriate treatment decisions and, ultimately, improve patients' care," said Prof. Patrick Vermersch (Lille, France), Coordinating Investigator and Chairman of the Study Steering Committee.

The MS-DETECT study will include 314 PwMS and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France. Several investigative sites have already been initiated in North America and Europe and first patients are expected to participate in the study during Q3 2023.
Check our LinkedIn, Facebook, Instagram pages or visit adscientiam.com

Contact Information
Saad Zinai
Chief Medical Officer
szinai@adscientiam.com
+33768008666

Matthieu Lamy
President
mlamy@adscientiam.com
+33768008666

話題 Press release summary


http://www.acnnewswire.com
From the Asia Corporate News Network

Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network


Latest Press Releases
Kincora Consolidates, Commences Geophysics and Forms Partnership at Cowal East  
Mar 10, 2026, 17:59 HKT/SGT
Fosun Navigates Cyclical Volatility and Clears Risks as Management Reaffirms RMB10 Bn Profit Target for Next 3 to 5 Yrs  
Mar 10, 2026, 15:45 HKT/SGT
Impro Precision 2025 Profit Attributable to Shareholders Reaches Record High of HK$726.2 Million, Up 12.7% Year-on-Year, Forecast 2026 Sales Growth Rate to Accelerate to Mid-Double Digits  
Mar 10, 2026, 14:19 HKT/SGT
Natural Beauty's 2025 Annual Results Show Steady & Robust Growth  
Mar 10, 2026, 13:35 HKT/SGT
Xiamen C&D Inc.'s New Five-Year Strategic Plan Released, Aiming to Accelerate Globalization  
Mar 10, 2026, 12:30 HKT/SGT
Fujitsu launches Japan's first defense tech open innovation program  
Tuesday, March 10, 2026 10:45:00 AM
Entertainment Expo Hong Kong shines on the centre stage, Eight signature events unite global film and entertainment forces  
Mar 9, 2026, 20:04 HKT/SGT
Raya Blooms in the Heart of Nature at Spritzer EcoPark  
Mar 9, 2026, 14:23 HKT/SGT
Huatai Securities Convenes 2026 Spring Investment Summit in Shanghai  
Mar 9, 2026, 14:15 HKT/SGT
Fujitsu and DT-Axis collaborate to advance digital health   
Monday, March 9, 2026 12:32:00 PM
More Press release >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
頂部 | 關於我們 | 服務 | 合作夥伴 | 聯繫 | 隱私權政策 | 使用條款 | RSS
美國: +1 214 890 4418 | 中國: +86 181 2376 3721 | 香港: +852 8192 4922 | 新加坡: +65 6549 7068 | 東京: +81 3 6859 8575